The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of immunotherapeutics for Alzheimer’s disease. The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease.
Read more about this report online at: http://www.insightpharmareports.com/
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com or contact Kerri Simpson at ksimpson@healthtech.com or 781-972-1347.
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/
